Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUV39H2 | Q9H5I1 | 17/20 | 0.41 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.40 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.40 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2092722 | 0.94 | PIM3 (0.45) | SUV39H2DYRK3PIM3SRPK1CSNK1G1 | |
| SCHEMBL2093107 | 0.94 | PIM3 (0.45) | SUV39H2DYRK3PIM3SRPK1CSNK1G1 | |
| SCHEMBL2092425 | 0.94 | PIM3 (0.45) | SUV39H2DYRK3PIM3SRPK1CSNK1G1 | |
| SCHEMBL2091583 | 0.92 | SUV39H2 (0.40) | SUV39H2DYRK3PIM3SRPK1CSNK1G1 | |
| SCHEMBL2094630 | 0.92 | SUV39H2 (0.40) | SUV39H2DYRK3PIM3SRPK1CSNK1G1 | |
| SCHEMBL2093143 | 0.92 | SUV39H2 (0.40) | SUV39H2DYRK3PIM3SRPK1CSNK1G1 | |
| SCHEMBL2092330 | 0.92 | SUV39H2 (0.40) | SUV39H2PDE10ASCN9A | |
| SCHEMBL2095944 | 0.89 | SUV39H2 (0.41) | SUV39H2PDE10ASCN9A | |
| SCHEMBL2094910 | 0.89 | SUV39H2 (0.41) | SUV39H2PDE10ASCN9A | |
| SCHEMBL2097591 | 0.88 | SUV39H2 (0.41) | SUV39H2DYRK3PIM3SRPK1CSNK1G1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163769-B2 | 1,8-naphthyridine derivatives | ABBOTT LABORATORIES (US) | 2012-04-24 | — | — | US | disclosed |
| US-20030232818-A1 | Antibacterial compounds | ABBVIE INC. | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232818-A1 | Antibacterial compounds | PGLS, UGT1A1, CASP1 | SUV39H2 4289/4885DYRK3 4599/4885PIM3 3424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.